Recent progress in synthetic self-adjuvanting vaccine development.
Biomater Sci
; 10(15): 4037-4057, 2022 Jul 26.
Article
en En
| MEDLINE
| ID: mdl-35708540
ABSTRACT
Vaccination is a proven way to protect individuals against many infectious diseases, as currently highlighted in the global COVID-19 pandemic. Peptides- or small molecule antigen-based vaccination offer advantages over the classical vaccine approaches. However, peptides or small molecules by themselves are generally not sufficiently immunogenic, and thus require an adjuvant to boost an immune response. Several conjugated systems have been developed in recent years to overcome this obstacle. This review summarises different moieties which, when conjugated to peptide antigens, facilitate a specific immune response. Different classes of self-adjuvant moieties are reviewed, including self-assembly peptides, lipids, glycolipids, and polymers.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
COVID-19
/
Desarrollo de Vacunas
Límite:
Humans
Idioma:
En
Revista:
Biomater Sci
Año:
2022
Tipo del documento:
Article
País de afiliación:
Australia